- Home
- CATO vs ATNM Comparison
CATO vs ATNM Comparison
Compare CATO & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- ATNM
- Stock Information
- Founded
- CATO 1946
- ATNM 2000
- Country
- CATO United States
- ATNM United States
- Employees
- CATO N/A
- ATNM N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- ATNM Health Care
- Exchange
- CATO Nasdaq
- ATNM Nasdaq
- Market Cap
- CATO 59.2M
- ATNM 51.5M
- IPO Year
- CATO N/A
- ATNM N/A
- Fundamental
- Price
- CATO $2.86
- ATNM $1.57
- Analyst Decision
- CATO
- ATNM Strong Buy
- Analyst Count
- CATO 0
- ATNM 3
- Target Price
- CATO N/A
- ATNM $4.67
- AVG Volume (30 Days)
- CATO 32.4K
- ATNM 492.9K
- Earning Date
- CATO 08-21-2025
- ATNM 08-04-2025
- Dividend Yield
- CATO 6.05%
- ATNM N/A
- EPS Growth
- CATO N/A
- ATNM N/A
- EPS
- CATO N/A
- ATNM N/A
- Revenue
- CATO $642,949,000.00
- ATNM N/A
- Revenue This Year
- CATO N/A
- ATNM N/A
- Revenue Next Year
- CATO N/A
- ATNM N/A
- P/E Ratio
- CATO N/A
- ATNM N/A
- Revenue Growth
- CATO N/A
- ATNM N/A
- 52 Week Low
- CATO $2.19
- ATNM $1.03
- 52 Week High
- CATO $6.70
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- CATO 64.69
- ATNM 52.22
- Support Level
- CATO $2.84
- ATNM $1.41
- Resistance Level
- CATO $3.05
- ATNM $1.63
- Average True Range (ATR)
- CATO 0.14
- ATNM 0.11
- MACD
- CATO 0.02
- ATNM 0.01
- Stochastic Oscillator
- CATO 100.00
- ATNM 59.72
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.